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Adeno-associated virus serotype-9 efficiently transduces the retinal
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Purpose: Adeno-associated virus serotype-9 (AAV-9) is a promising gene delivery vector. In this study, we evaluated
AAV-9 transduction in the mouse retina.
Methods:  Three  different  AAV  vectors  were  used  in  our  study:  AAV-9.RSV.AP,  AAV-9.CMV.eGFP,  and
AAV-9.CMV.∆R4–23/∆C. In these vectors, two different promoters (the cytomegalovirus promoter-CMV promoter and
the Rous sarcoma virus-RSV promoter) were used to express three different transgenes including the alkaline phosphatase
(AP) gene, the enhanced green fluorescent protein (eGFP) gene, and a therapeutic microdystrophin gene (the ∆R4–23/
∆C). Specifically, 1 µl AAV-9 reporter gene vectors (1×109 viral genome particles of AAV-9.RSV.AP or 1×1010 viral
genome particles of AAV-9.CMV.eGFP) were administered subretinally to young (2–3-week-old), adult (3-month-old),
and old (12-month-old) C57BL/6J mice. To evaluate AAV-9 transduction in a diseased retina, we injected subretinally
1×109 viral genome particles of AAV-9.CMV.∆R4–23/∆C to mdx3cv mice, which we used as a model for Duchenne
muscular dystrophy (DMD). Transgene expression was examined by histochemical as well as immunofluorescence
staining  at  three  and  five  weeks  after  injection.  Electroretinograms  were  recorded  five  weeks  after  subretinal
AAV-9.RSV.AP injection.
Results: Subretinal injection yielded widespread transduction throughout the retina in all age groups. Robust expression
was seen in the retinal pigment epithelium, outer nuclear layer, and in Müller cells. Interestingly a synaptic layer, the outer
plexiform layer (OPL), also showed intensive expression. Transduction of the synaptic layer was further confirmed by
immunostaining for C-terminal binding protein 2 (CtBP2), a marker for the photoreceptor synaptic ribbon. Dystrophin is
normally expressed in the OPL photoreceptor terminals. This expression is lost in DMD patients and mdx3cv mice.
Consistent  with  our  findings  in  normal  mice,  we  observed  efficient  microdystrophin  expression  in  the  OPL  after
AAV-9.CMV.∆R4–23/∆C infection. At five weeks after subretinal delivery of AAV-9.RSV.AP, no morphology or ERG
abnormalities were observed.
Conclusions: We demonstrated that AAV-9 is a potent vector for retinal gene delivery. Furthermore, subretinal AAV-9
administration did not cause appreciable acute retinal damages. In summary, AAV-9-mediated OPL transduction holds
promise for treating diseases that primarily affect this layer.
Adeno-associated virus (AAV) is a single-stranded DNA
virus. AAV-mediated gene therapy has successfully corrected
several degenerative retinal diseases in animal models [1-4].
Recent successes in Leber congenital amaurosis phase I trials
have provided the first clinical proof that AAV vector holds
great promise in treating retinal diseases [5-8].
Recombinant AAV vectors are generated by replacing the
endogenous viral genome with a therapeutic or marker gene
expression cassette. The prototype AAV vector is based on
AAV serotype-2 (AAV-2). In the last few years, several new
AAV  serotypes  have  been  developed  [9].  Due  to  the
differences in the cellular transduction pathway, these new
serotypes have opened additional avenues for tailoring AAV
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gene therapy to specific clinical applications. Previous studies
have evaluated AAV serotypes 1–9 in the retina [3,10-13]. It
was found that subretinal injection transduces the outermost
retinal structures, such as retinal pigment epithelium (RPE)
and the photoreceptors, while intravitreal injection transduces
ganglion cells in the innermost layer. Pathology in the retinal
synaptic layers such as the outer plexiform layer (OPL) is
associated with a wide range of retinal diseases [14-18]. Two
recent studies suggest that AAV may transduce the OPL [12,
19]. However, these studies did not explicitly explore the
specificity of OPL transduction. Considering the importance
of the OPL in retinal diseases, a thorough and more focused
study would be necessary to establish AAV transduction in
the OPL. Such efforts would likely open the door for AAV-
mediated OPL disease gene therapy.
AAV serotype-9 (AAV-9) was discovered a few years
ago from human tissue [9,20]. Due to its unique serological
property, it was classified as clade F, a clade distinctive from
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1374all known AAVs [20]. AAV-9 has been shown to efficiently
transduce  several  tissues  including  the  heart,  liver,  lung,
kidney, pancreas, and skeletal muscle [21-27]. Furthermore,
it was reported recently that AAV-9 is capable of bypassing
the blood-brain barrier and efficiently targeting cells of the
central nervous system [21]. This unique feature may enable
the  development  of  gene  therapies  for  a  range  of
neurodegenerative diseases. Two studies evaluated AAV-9
transduction in the retina following subretinal administration
[12,13]. Both studies demonstrated efficient transduction of
RPE  and  Müller  cells  [12,13].  Interestingly,  one  group
showed photoreceptor transduction [12]. However, the other
group did not detect photoreceptor transduction [13]. The
reasons for these differences are not clear but may relate to
animal age, the promoter and the reporter gene used, and the
time frame of observation. To further characterize AAV-9
transduction in the retina, we performed a comprehensive
study in young (2–3-week-old), adult (3-month-old), and old
(12-month-old)  mice  using  either  an  Rous  sarcoma  virus
promoter (RSV) driving alkaline phosphatase reporter gene
vector  (AAV-9.RSV.alkaline  phosphate  [AP])  or  a
Cytomegalovirus promoter (CMV) driving enhanced green
fluorescent  protein  (AAV-9.CMV.enhanced  green
fluorescent protein [eGFP]) reporter gene vector. To further
extend the study, we also evaluated subretinal delivery of a
therapeutic microdystrophin vector (AAV-9.CMV.∆R4–23/
∆C) in adult mdx3cv mice, a model for Duchenne muscular
dystrophy  (DMD).  We  observed  widespread  transduction
throughout  the  retina  following  subretinal  injection.
Interestingly,  we  observed  remarkable  transduction  in  the
synaptic OPL irrespective of the vector used. Colocalization
experiments with a marker of the photoreceptor presynaptic
ribbon  further  confirmed  the  OPL  transduction.  To  our
knowledge, this is the first demonstration of efficient retinal
synaptic layer transduction by an AAV vector. Besides tissue
tropism, we also evaluated acute toxicity of subretinal AAV-9
injection. Our results suggest that subretinal AAV-9 delivery
was  not  associated  with  deleterious  effect  on  retinal
morphology and electroretinogram (ERG) function.
METHODS
Experimental animals: All experiments were conducted in
accordance with the Association for Research in Vision and
Ophthalmology  Statement  for  the  Use  of  Animals  in
Ophthalmic and Vision Research. The experimental protocols
were reviewed and approved by institutional animal care and
use committee at the University of Missouri. C57BL/6J and
mdx3cv  mice  were  originally  purchased  from  The  Jackson
Laboratory  (Bar  Harbor,  ME).  Experimental  mice  were
obtained from local breeding colonies. All mice were housed
in specific pathogen-free (SPF) animal care facilities and kept
under a 12 h:12 h light-dark cycle (25 lx) with free access to
food and water.
Recombinant  AAV-9  production:  AAV-9  stocks  were
generated  using  an  adenoviral  free  triplasmid  transfection
protocol described previously [22,23]. Briefly, 70% to 80%
confluent 293 cells were cotransfected with a cis-plasmid, a
pRep2/Cap9 helper plasmid (a gift from Dr. James M. Wilson,
University  of  Pennsylvania,  Philadelphia,  PA)  and  an
adenoviral  helper  plasmid  (pHelper;  Stratagene,  La  Jolla,
CA). Crude viral lysate was harvested 72 h later and purified
through two rounds of CsCl isopycnic ultracentrifugation.
Purified  virus  was  dialyzed  through  three  exchanges  of
HEPES buffered saline at 4 °C. Viral titer determination and
quality control were performed as described before [22,23].
Briefly, viral DNA was extracted and slot blot hybridization
was performed using P32-labeled radioactive probe. Vector
genome  was  determined  according  to  the  plasmid  copy
number standards. The absence of significant wild type AAV
contamination  was  confirmed  by  immunofluorescence
staining with an antibody that recognizes AAV Rep protein.
The  cis-plasmids  (pcisRSV.AP,  pcisCMV.eGFP,  and
pcisCMV.∆R4–23/∆C) have been reported previously [24,
25]. pcisRSV.AP expresses the heat-resistant human placental
AP gene under the transcriptional control of the RSV promoter
and the SV40 polyadenylation signal (pA). pcisCMV.eGFP
expresses the eGFP gene under the transcriptional control of
the CMV promoter and the SV40 pA. pcisCMV.∆R4–23/∆C
encodes  a  highly  abbreviated  ∆R4–23/∆C  human
microdystrophin gene under the transcriptional control of the
CMV and the SV40 pA [28]. Specifically, a large portion of
the dystrophin rod domain (from spectrin-like repeat 4 to 23)
and  the  entire  C-terminal  domain  are  deleted.  The
recombinant  AAV  vectors  are  called  AAV-9.RSV.AP,
AAV-9.CMV.eGFP, and AAV-9.CMV.∆R4–23/∆C.
Subretinal  injection:  AAV-9.RSV.AP  and
AAV-9.CMV.eGFP injection were delivered to young (2- to
3-week-old),  adult  (3-month-old),  and  old  (12-month-old)
C57BL/6J  mice.  AAV-9.CMV.∆R4–23/∆C  injection  was
delivered to 3-month-old adult mdx3cv mice. HEPES-buffered
saline was used as vehicle control in a subset of animals.
Mice were given 1% atropine eyedrops 3 h before they
were  anesthetized  with  an  intraperitoneal  injection  of  a
mixture  of  75  mg/kg  ketamine  and  13.6  mg/kg  xylazine.
Following  general  anesthesia,  2.5%  phenylephrine
hydrochloride  eyedrops  were  applied.  One  drop  of  1%
proparacaine  hydrochloride  was  administered  as  local
anesthesia, followed by 2.5% hydroxypropyl methylcellulose.
Subretinal injection was performed according to a previous
publication  with  modifications  [29].  Briefly,  an  aperture
within the pupil area was made through the superior cornea
with a 30-gauge needle. A 33-gauge blunt needle mounted on
a 10-μl syringe was introduced through the corneal opening,
avoiding the lens and penetrating the neuroretina to reach the
posterior  subretinal  space.  The  NanoFil™  sub-microliter
injection system (WPI, Sarasota, FL) was used to inject 1 µl
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1375of  AAV  vector  in  30  s.  The  injection  was  considered
successful when retinal blebs occupied more than half of the
retina.  Evaluation  was  performed  only  in  mice  that  were
successfully  injected.  Following  subretinal  injection,  1%
atropine eyedrops and antibiotic ophthalmic ointment were
administered daily for three days. Seven days after injection,
the mice were anesthetized with ketamine and xylazine as
described previously, and their eyes were examined under
microscope.  Eyes  that  exhibited  any  sign  of  surgical
complications,  including  anterior  or  posterior  synechia,
cataract,  vitreous  and  retinal  hemorrhage,  and  unresolved
Figure  1.  Representative  retinal  cross
sections  of  C57BL/6J  mice  after
subretinal delivery of AAV-9.RSV.AP.
Panels A and B show global view of
AAV-9 transduction in adult (3-month-
old) C57BL/6J mouse eyes at 5 weeks
after  subretinal  AAV-9.RSV.AP
injection  (A)  and  HEPES  buffer
injection  (B).  Yellow  arrows  indicate
the injection sites. Panels C and D show
the  enlarged  retinal  sections  of  the
boxed regions in A and B, respectively.
Panels E and F are representative retinal
sections obtained from young (3-week-
old)  mice  at  3  weeks  after  subretinal
injection. E shows the area close to the
injection  site  while  F  shows  an  area
distant from the injection site. Panels G
and H are representative retinal sections
obtained  5  weeks  after  subretinal
injection in a 12-month-old mouse. G
shows the area close to the injection site
while H shows an area distant from the
injection  site.  Similar  AP  expression
pattern  can  be  seen  in  all
AAV-9.RSV.AP-injected  eyes.  Dark
blue  AP  staining  is  readily  visible
throughout the entire retina. The RPE,
ONL,  INL,  and  RGC  layers  show
punctate  staining.  AP-positive  Müller
cells display staining across majority of
the retina thickness from the ONL to the
RGC layers. AP expression in the OPL
and  the  IPL  layers  is  prominent.
Although staining in the region distant
from the injection site is weaker, AP
expression  is  widespread  in  the  two
synaptic  layers.  Representative
photomicrograph from a HEPES buffer
mock-infected eye shows no evidence of
AP expression. Yellow arrows mark the
injection site; red arrows indicate outer
plexiform layer (OPL); red arrowheads
indicate  inner  plexiform  layer  (IPL);
green  arrows  indicate  Müller  cells;
yellow  arrowheads  indicate  RPE.
Abbreviations:  alkaline  phosphatase
(AP), inner nuclear layer (INL), outer
nuclear  layer  (ONL),  retinal  ganglion
cell (RGC), retinal pigment epithelium
(RPE).
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1376retinal detachment, were excluded from the study. Such signs
were observed in 20% to 30% of the eyes.
Retinal  morphology  and  gene  expression:  For  AP  and
dystrophin expression, mouse eyes were enucleated and snap
frozen in liquid nitrogen–cooled isopentane in optimal cutting
temperature  (OCT)  compound  (Sakura  Finetek  Inc.,
Torrance, CA). Next, 10 µm cryosections were cut along the
optic nerve head and stained with hematoxylin and eosin
Figure 2. Retinal eGFP expression after
subretinal  delivery  of  an
AAV-9.CMV.eGFP  vector  in  a  3-
month-old  C57BL/6J  mouse.  AAV-9
led to widespread (from the injection
site, which is close to the posterior pole,
to the peripheral retina) and throughout
(from the outer retina RPE layer to the
inner  retina  RGC  layer)  eGFP
expression  in  the  mouse  retina.  The
eGFP  expression  pattern  near  the
injection site and in areas remote from
the  injection  site  was  similar.  The
pictures  were  taken  at  approximately
300 to 500 µm away from the injection
site.  A-C  were  taken  under  the  same
exposure  conditions.  D-H  were  taken
with  a  shorter  exposure  time.  A  is  a
section  from  a  control  eye.  B  shows
eGFP expression in the retina, and C is
a  merged  picture  of  B  and  DAPI
staining. B and C show GFP expression
in the RPE, photoreceptors (including
the  outer  and  inner  segment),  ONL,
OPL, Müller cells in the INL, IPL and
RGC  layer.  Because  of  a  shorter
exposure  time  (D),  eGFP  expression
was  only  seen  in  the  outer  retina
including  RPE  and  the  photoreceptor
layer. No expression was observed in
the inner retina. E is a merged picture of
eGFP  expression  and  CtBP2,  DAPI
staining. In the distal portion of the OPL,
colocalization of eGFP expression and
CtBP2 staining is evident (arrow). F,
G, and H are enlarged pictures of the
OPL. F. eGFP expression is evident in
the distal portion of the OPL, which is
beyond  the  photoreceptor  nuclei  (in
blue). G shows CtBP2 staining (arrow)
in the photoreceptor terminals. Panel H
is a merged picture of eGFP expression
and  CtBP2,  DAPI  staining.  eGFP
expression overlaps with CtBP2 in the
photoreceptor  terminals  in  the  distal
portion of the OPL The calibration bar
is 50 μm for A-E, and 20 μm for F-H.
Abbreviations:  inner  nuclear  layer
(INL), inner plexiform layer (IPL), outer
nuclear  layer  (ONL),  outer  plexiform
layer  (OPL),  retinal  ganglion  cell
(RGC),  retinal  pigment  epithelium
(RPE).
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1377(H&E) for routine retinal morphology. After endogenous heat
labile AP activity was heat inactivated, AAV-9 mediated AP
expression was examined by histochemical staining using a
previously  described  protocol  [22-24].  Microdystrophin
expression was evaluated by immunofluorescence staining
according to a previously published protocol [30]. Briefly,
cryosections were sequentially blocked with Papain-digested
rabbit anti-mouse immunoglobulin and rabbit serum. Then
sections  were  stained  with  the  primary  anti-dystrophin
antibody and signal was detected with appropriate secondary
antibodies. The present study employed 1:30 Dys-2 antibody
(Novocastra, Newcastle, UK), which recognizes dystrophin
C-terminal domain and 1:20 Dys-3 antibody (Novocastra),
which recognizes the hinge 1 region in human dystrophin.
Also used was 1:100 Alexa Fluor 594-conjugated goat anti-
mouse IgG (H+L) F(ab’)2 fragment antibody as the secondary
antibody  in  immunofluorescence  staining  (Invitrogen,
Carlsbad, CA). For eGFP and CtBP2 detection, the eyeballs
were  first  fixed  in  4%  paraformaldehyde  and  phosphate-
buffer  saline  (PBS,,  0.01  M  phosphate  buffer,  0.0027  M
potassium chloride and 0.137 M sodium chloride, pH 7.4) then
cryoprotected in 30% sucrose/PBS overnight. Next, 10 µm
cryosections were stained with 1:200 goat anti-CtBP2 (C-
terminal binding protein 2, Santa Cruz, Biotechnology, Santa
Cruz, CA) followed by 1:500 Texas Red conjugated donkey
anti-goat IgG secondary antibody (Jackson ImmunoResearch,
West  Grove,  PA).  Nuclei  were  revealed  with  1:500  4’,6-
diamidino-2-phenylindole,  dihydrocholoride  (DAPI,
Molecular  Probes,  Eugene,  OR).  The  specificity  of
immunostaining was confirmed by staining cryosections in
the absence of the primary antibody. Photomicrographs were
taken  with  a  digital  camera  using  a  Leica  fluorescence
microscope (DMR, Deerfield, IL).
Electroretinography:  Retinal  function  was  evaluated  at  5
weeks after subretinal injection. Both dark- and light-adapted
ERG  were  examined  according  to  a  previously  published
protocol [31,32].
Statistical  analysis:  Data  are  presented  as  mean±standard
deviation (mean±SD). Statistical significance was examined
with ANOVA followed by the Tukey post hoc test. A p value
of less than 0.05 was considered as significant.
Figure  3.  Retinal  microdystrophin
expression in gene transferred 3-month-
old mdx3cv mouse. Subretinal delivery of
an  AAV-9  human  microdystrophin
vector  resulted  in  efficient  OPL
transduction in mdx3cv mouse retina. A-
F are from mdx3cv mouse eyes, and G is
from a C57BL/6J mouse eye. A-C are
representative  serial  sections  from  an
eye  infected  with  AAV-9
microdystrophin  vector.  D-F  are
representative  serial  sections  from  an
eye mock-infected with HEPES buffer.
A, D show retinal structure of mdx3cv
mouse  (H&E  staining).  B,  E  show
immunostaining  with  the  Dys-3
antibody,  which  recognizes
microdystrophin.  At  5  weeks  after
subretinal  injection,  microdystrophin
expression was evident in the injected
retina (B), but not in the mock-infected
eye  (E).  C  and  F  display
immunostaining  with  the  Dys-2
antibody, which recognizes endogenous
dystrophin. Neither the AAV-9-infected
nor  the  mock-infected  eye  showed
endogenous  dystrophin  expression.  G
shows immunostaining with the Dys-2
antibody  on  the  C57BL/6J  retina.
Dystrophin  expression  is  seen  in  the
outer  plexiform  layer  (OPL).  Arrows
point to the OPL. Abbreviations: inner
nuclear layer (INL), outer nuclear layer
(ONL).
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1378RESULTS
We first examined subretinal AAV-9 AAV.RSV.AP injection
in normal C57BL/6J mice. Figure 1 shows the representative
retinal cross-sections from young (n=6 eyes, 3 weeks post-
injection), adult (n=12 eyes, 5 weeks post-injection) and old
(n=5 eyes, 5 weeks post-injection) mice. AAV-9 resulted in
widespread  (peripheral  to  central  to  peripheral)  and
throughout  (RPE  to  retinal  ganglion  cells  [RGC])  AP
expression in all age groups (Figure 1A, data not shown for
young and old mice). Nevertheless, the highest expression
was observed at the injection site (Figure 1A, arrow). AP
expression  was  observed  in  the  RPE,  outer  nuclear  layer
(ONL), inner nuclear layer (INL), OPL, inner plexiform layer
(IPL), RGC layer and Müller cells but not the outer and inner
segments of the photoreceptor (Figure 1C,E-H). Remarkably,
two  retinal  synaptic  layers  (OPL  and  IPL)  were  highly
transduced (Figure 1C,E-H). AP expression was not detected
in the mock-infected control eyes (5 eyes each for young and
adult mice; Figure 1B,D).
Figure 4. Effects of subretinal delivery of an AAV-9.RSV.AP vector
on  mouse  electroretinogram.  Dark-adapted  and  light-adapted
electroretinograms  were  recorded  from  12-month-old  C57BL/6J
mice at 5 weeks after subretinal injection of AAV-9.RSV.AP or
HEPES buffer. One eye was injected and the contralateral eye was
untreated. Black arrows indicate OPs. The numbers to the left of the
ERG signals represent the stimulus light intensity (log cd-s/m2). The
background light for light-adaptation was 30 cd/m2.
To exclude the potential bias from the transgene as well
as  the  promoter,  we  evaluated  AAV-9.CMV.eGFP
transduction (4 eyes in 2-week-old and 4 eyes in 3-month-old
mice). Four weeks after subretinal injection, we observed
intense eGFP expression in young and adult groups in the
RPE, ONL, INL, OPL, IPL, RGC layers, and Müller cells
(Figure  2B,C).  Interestingly,  we  also  observed  robust
expression in the photoreceptors (Figure 2B-E). To further
confirm OPL transduction, we stained AAV-9.CMV.eGFP-
infected eyes with CtBP2, a marker for the photoreceptor
synaptic ribbon (Figure 2 E,G,H). The colocalization of eGFP
and CtBP2 strongly suggest that the OPL layer was transduced
(Figure 2F,H).
OPL defects are associated with several retinal diseases.
To  determine  whether  AAV-9  can  be  used  to  deliver  a
therapeutic  gene  to  the  OPL,  we  performed  subretinal
injection  in  mdx3cv  mice  using  AAV-9.CMV.∆R4–23/∆C
vector. Mdx3cv mice are models for DMD, a lethal childhood
genetic disease caused by mutations in the dystrophin gene
[33,34]. Besides muscle disease, DMD patients also suffer
from  pathology  in  other  systems  such  the  central  nerve
system. A 260 kDa dystrophin isoform (Dp260) is normally
expressed in the OPL. In the eyes of DMD patients and mdx3cv
mice, Dp260 expression is lost [35-37]. The absence of Dp260
has been associated with the abnormal ERG seen in DMD
patients.
The  3.8  kb  ∆R4–23/∆C  microgene  encodes  a  highly
truncated dystrophin. This microgene has been extensively
studied as a candidate gene for DMD gene therapy [28]. At 5
weeks  after  subretinal  injection  (n=5  mice;
AAV-9.CMV.∆R4–23/∆C to one eye and HEPES buffer to
the contralateral eye), we evaluated dystrophin expression by
immunofluorescence  staining.  Two  epitope-specific
antibodies  were  used  in  the  study.  The  Dys-2  antibody
recognizes endogenous Dp260 in the wild type retina (Figure
3G)  [38],  while  the  Dys-3  antibody  only  reacts  with
microdystrophin.  Consistent  with  our  findings  in  reporter
AAV vector-infected normal eyes, we observed efficient OPL
transduction in the eyes of AAV-9.CMV.∆R4–23/∆C infected
mdx3cv mice (Figure 3B,C). No dystrophin was detected in
HEPES buffer-injected eyes (Figure 3E,F).
Next, we studied whether subretinal AAV-9 injection
causes  acute  retinal  damage.  At  5  weeks  after  subretinal
injection  (AAV-9.RSV.AP  or  HEPES)  in  adult  and  old
C57BL/6J mice (n=5 for each age group), we examined retinal
histology and recorded dark-adapted and light-adapted ERGs.
Compared  with  untreated  eyes,  neither  HEPES  buffer
injection  nor  AAV-9.RSV.AP  injection  resulted  in
appreciable morphology alterations (Figure 4). In each age
group, the thresholds and amplitudes of the dark-adapted ERG
a-wave, dark-adapted b-wave and light-adapted b-wave of the
AAV-9 or HEPES injected eyes were comparable to those of
the untreated eyes (p>0.05, Figure 4, Figure 5, and Figure 6).
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1379On the ascending limb of dark-adapted b-wave, the amplitude
of  the  oscillatory  potentials  (OPs)  in  the  AAV-9  vector
injected eyes appeared smaller than the untreated eyes (Figure
4). However, similar reduction was also observed in HEPES-
injected eyes.
DISCUSSION
AAV-mediated gene therapy holds great promise for rescuing
vision  loss  in  retinal  degenerative  diseases.  Remarkable
progress has been made in animal models and human patients
[1,2,4,6-8]. However, most studies have focused on diseases
that primarily affect the photoreceptor, RPE, and RGC layer.
There are two synaptic layers in the retina including the
OPL in the outer retina and the IPL in the inner retina. The
OPL and IPL are indispensable for mediating visual signal
transmission. While no human diseases have been associated
with the IPL, several retinal diseases originate in as well as
primarily affect the OPL. Examples of these diseases include
congenital  stationary  night  blindness,  retinoschisis,  DMD
retinopathy, and melanoma-associated retinopathy [14-18].
Gene therapy for these diseases is largely dependent on a
vector that can efficiently deliver the therapeutic genes to the
OPL.
Several different AAV serotypes have been evaluated for
retinal  gene  delivery.  In  this  study  we  examined  AAV-9
transduction in young, adult, and old mice. Consistent with
recent  publications  from  other  investigators,  we  observed
robust  AAV-9  transduction  in  the  outer  retina  (RPE  and
ONL), inner retina (Müller cells), and RGC layers [12,13].
Figure 5. Dark-adapted ERG a-wave and b-wave responses-intensity
curves  in  C57BL/6J  mice.  In  all  animals,  one  eye  was  injected
subretinally while the contralateral eye was untreated. A, B show
HEPES-treated mice and C, D show AAV-9.RSV.AP-injected mice.
The left column shows the 3-month-old groups (n=5 for each group)
and the right column shows the 12-month-old groups (n=5 for each
group). The filled symbols represent the injected eyes, and the open
symbols represent the untreated eyes. Error bars indicate the standard
deviation from the mean (mean±SD).
Surprisingly, we also observed quite efficient and widespread
transduction in the synaptic layers (Figure 1, Figure 2, and
Figure 3). A colocalization study suggested that transduction
occurred in the photoreceptor terminals, but not in the bipolar
cell and horizontal cell dendrites in the OPL (Figure 2).
To  explore  therapeutic  gene  delivery  to  the  OPL  we
delivered AAV-9.CMV.∆R4–23/∆C to adult mdx3cv mice. We
focused  on  transgene  expression  rather  than  functional
correction in this study. Consistent with our findings in normal
mice, we observed robust microdystrophin expression in the
OPL.  Taken  together,  our  results  suggest  that  AAV-9-
mediated OPL transduction represents a promising approach
to treat retinal diseases that are related to OPL defects.
It  is  important  to  understand  whether  subretinal
administration of a new viral vector causes any side effects.
We found that subretinal delivery of AAV-9 did not alter
retinal structure. In addition, rod and cone photoreceptor and
bipolar cell functions were not affected by subretinal AAV-9
injection (Figure 4, Figure 5, and Figure 6). Interestingly the
OPs, highly sensitive functional indicators of the inner retina
[39], were reduced following AAV-9 injection. Since similar
reductions  were  also  observed  in  HEPES-buffer-injected
eyes. We suspect that the OP reduction may relate to the
injection procedure rather than AAV-9 vector.
Taken together, our data suggest that AAV-9 is a potent
vector for retina gene delivery, and subretinal administration
does not cause acute damage. Efficient transduction of the
photoreceptor terminals opens the door to develop AAV-9
Figure 6. Light-adapted ERG b-wave responses-intensity curves in
C57BL/6J mice. In all the animals, one eye was injected subretinally
while the contralateral eye was not treated. A, B show HEPES-treated
mice and C, D show AAV-9.RSV.AP-injected mice. The left column
shows the 3-month-old groups (n=5 for each group), and the right
column shows the 12-month-old groups (n=5 for each group). The
filled symbols represent the injected eyes, and the open symbols
represent the untreated eyes. Background light was 30 cd/m2. Error
bars indicate the standard deviation from the mean (mean±SD).
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